NCT04625153View on ClinicalTrials.gov

RC18 in Patients With Relapsing Remitting Multiple Sclerosis：a Phase II Trial

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 13, 2021

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
BIOLOGICAL

RC18 160mg

RC18 160mg is injected subcutaneously once a week for 48 times.

BIOLOGICAL

RC18 240mg

RC18 240mg is injected subcutaneously once a week for 48 times.

Trial Locations (1)

Unknown

RECRUITING

the Third Affiliated Hospital,Sun Yat-Sen University, Guangzhou

All Listed Sponsors
lead

RemeGen Co., Ltd.

INDUSTRY